Investment
Features
FeesSafety
Academy
More
Pluang+

Sangoma beats EPS estimates but misses revenue; acquisition deal boosts shares 35%.

Company Fundamentals
29 Sep 2026
Gordon Thompson
View Source
Bullish
Sangoma beats EPS estimates but misses revenue; acquisition deal boosts shares 35%.

Sangoma Technologies reported a smaller-than-expected loss with an EPS of -$0.08, beating analyst estimates of -$2.19, though its revenue of $48.55 million slightly missed expectations. Despite ongoing profitability challenges reflected in a negative P/E ratio, the company's shares surged over 35% following news of its acquisition by BRC Group Holdings at a 47% premium, valuing Sangoma at around $204 million. This acquisition offers significant shareholder value and marks a key development for the communications solutions provider.

Sangoma Technologies is the story subject, here is Pluang's Technology sector snapshot as of Sep 30, 2026 03:02 WIB: Among 150 priced US tech stocks, 63 rose and 87 fell. Notable movers include TEAM at USD 178.28 with a -5.04% change and 100% buy order activity, NTES at USD 120.95 up 4.80% with 80% buy orders, and GLW at USD 158.77 up 4.80% with 86% sell orders.

More News

Micron projects record $51.33B revenue driven by AI memory demand, with EPS soaring to $31.72 this quarter.

Micron projects record $51.33B revenue driven by AI memory demand, with EPS soaring to $31.72 this quarter.

Micron Technology is set to report record quarterly revenue of up to $51.33 billion, fueled by strong demand for high-bandwidth memory in the AI market. Earnings per share are expected to jump significantly to around $31.72, compared to $3.03 last ye...

Company Fundamentals
Bullish
15 minutes ago
Iovance Biotherapeutics raises 2026 revenue forecast with strong Q2 sales and analyst optimism.

Iovance Biotherapeutics raises 2026 revenue forecast with strong Q2 sales and analyst optimism.

Iovance Biotherapeutics has increased its full-year 2026 revenue guidance to $410-$420 million, reflecting nearly 60% growth driven by strong U.S. demand for its cancer therapy Amtagvi, which generated $91 million in Q2 sales. Analyst Joseph Pantgini...

Analyst Insights
Bullish
3 hours ago
uniQure shares drop 37% after mixed results in Huntington's gene therapy trial

uniQure shares drop 37% after mixed results in Huntington's gene therapy trial

uniQure's stock fell sharply by 37% following a four-year update on its AMT-130 gene therapy for Huntington's disease, which showed reduced effectiveness from 80% at three years to 44% at four years, failing to reach statistical significance. Despite...

Market News
Bearish
3 hours ago
First Financial Bank to open new full-service branch in Bee Cave, Texas, expanding in Austin area.

First Financial Bank to open new full-service branch in Bee Cave, Texas, expanding in Austin area.

First Financial Bank, a subsidiary of First Financial Bankshares, Inc., announced it will open a new full-service branch in Bee Cave, Texas, in late October. This marks the bank's 81st location and strengthens its presence in Central Texas and the gr...

Market News
Bullish
4 hours ago
Republic Services to report Q3 2026 earnings on Oct 29 with live investor call.

Republic Services to report Q3 2026 earnings on Oct 29 with live investor call.

Republic Services, a leading environmental services company, will announce its third quarter 2026 financial results after market close on October 29, 2026. The company will host a live investor conference call at 5 p.m. Eastern Time the same day, acc...

Company Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App